Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Walter

Showing results (291-300 of 334) with videos related to

Pageof 34
Sort By:
United European Gastroenterology Journal|October 31, 2019
Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE)Caroline Fine, Guillaume Roquin, Eric Terrebonne, et al.
The Lancet. Oncology|February 5, 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trialThomas Walter, Astrid Lievre, Romain Coriat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O<sup>6</sup>-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)Thomas Walter, Thierry Lecomte, Julien Hadoux, et al.
The Journal of Clinical Endocrinology and Metabolism|December 23, 2021
Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their DiseaseClément Mennetrey, Maëlle Le Bras, Aurélie Bando-Delaunay, et al.
Cancers|November 11, 2022
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA CohortGaël S Roth, Yohan Fayet, Sakina Benmameche-Medjahed, et al.
EMBO Molecular Medicine|March 6, 2023
From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumorsDavid Kryza, Jennifer Wischhusen, Mathieu Richaud, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 21, 2017
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II studyThomas Walter, David Malka, Olivia Hentic, et al.
Journal of Medicinal Chemistry|May 30, 2003
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritisVenkatesan Aranapakam, Jamie M Davis, George T Grosu, et al.
Endocrine-Related Cancer|August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC studyJulien Hadoux, Thomas Walter, Christina Kanaan, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
Pageof 34

Showing results (291-300 of 334) with videos related to

Sort By:
Pageof 34
United European Gastroenterology Journal|October 31, 2019
Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE)Caroline Fine, Guillaume Roquin, Eric Terrebonne, et al.
The Lancet. Oncology|February 5, 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trialThomas Walter, Astrid Lievre, Romain Coriat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O<sup>6</sup>-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)Thomas Walter, Thierry Lecomte, Julien Hadoux, et al.
The Journal of Clinical Endocrinology and Metabolism|December 23, 2021
Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their DiseaseClément Mennetrey, Maëlle Le Bras, Aurélie Bando-Delaunay, et al.
Cancers|November 11, 2022
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA CohortGaël S Roth, Yohan Fayet, Sakina Benmameche-Medjahed, et al.
EMBO Molecular Medicine|March 6, 2023
From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumorsDavid Kryza, Jennifer Wischhusen, Mathieu Richaud, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 21, 2017
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II studyThomas Walter, David Malka, Olivia Hentic, et al.
Journal of Medicinal Chemistry|May 30, 2003
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritisVenkatesan Aranapakam, Jamie M Davis, George T Grosu, et al.
Endocrine-Related Cancer|August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC studyJulien Hadoux, Thomas Walter, Christina Kanaan, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
Pageof 34